Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

IND submission to begin clinical testing of Tarvacin

Sep. 28, 2004

IDM cleared to begin U.S. phase II trial of Uvidem

Sep. 23, 2004

Phase III trial for Ceplene fails to meet primary endpoint

Sep. 23, 2004

New phase I data on the safety profile of cantuzumab mertansine in advanced cancer

Sep. 21, 2004

Novel DNA cancer vaccine enters phase I trial

Sep. 21, 2004

Phase I trial investigates GVAX prostate cancer vaccine with MDX-010

Sep. 15, 2004

H3 Pharma and DSM sign manufacturing agreement for SC-1

Sep. 14, 2004

Multikine lowers cholesterol in clinical studies

Sep. 14, 2004

Advanced Viral Research plans IND filing for injectable AVR-118

Sep. 13, 2004

HGS-ETR1 advanced into phase II

Sep. 13, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 6, 2026.
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Slate Medicines launches with focus on headache disorders
BioWorld Science
Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...